About this trial
To learn if Hyperpolarized C-Pyruvate Magnetic Resonance (HP-MR) Spectroscopic Imaging can help doctors detect low-risk (benign) and high-risk (malignant) cysts.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients ≥ 18 years old. Patients under 18 are excluded due to their potential inability to understand and consent independently to the methods required for the study drug use and its potential risks and benefits.
Patients with pancreatic cyst/s
Patients who will undergo surgical resection (or cyst wall biopsy) of pancreatic cysts
Patients able to understand and willing to sign a written informed consent document
Disqualifiers
Contraindication to MRI
Electrically, magnetically, or mechanically activated implants that would preclude MRI
Allergy to Gadavist IV contrast
History of cardiac arrhythmias
Trial design
Single group
Treatments tested in this trial
Hyperpolarized 13-C-pyruvate
DrugGiven by Injection
Treatment groups
Trial outcomes
Primary outcomes
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Sponsors and contacts
Click on the lead sponsor to view all of their trials.